Valuation: LivaNova PLC

Market Cap 4.29B 3.72B 3.47B 3.19B 6.02B 408B 6.09B 40.73B 15.99B 204B 16.12B 15.77B 676B P/E 2026 *
24.8x
P/E 2027 * 23.2x
Enterprise Value 4.29B 3.72B 3.47B 3.19B 6.02B 408B 6.09B 40.73B 15.99B 204B 16.12B 15.77B 676B EV / Sales 2026 *
2.84x
EV / Sales 2027 * 2.65x
Free-Float
98.44%
Yield 2026 *
-
Yield 2027 * -
1 day-8.41%
1 week-4.03%
Current month-2.49%
1 month-6.55%
3 months+35.69%
6 months+20.17%
Current year+27.00%
1 week 75.07
Extreme 75.07
85.76
1 month 75.07
Extreme 75.07
85.76
Current year 56.44
Extreme 56.44
85.76
1 year 47.13
Extreme 47.13
85.76
3 years 32.48
Extreme 32.48
85.76
5 years 32.48
Extreme 32.48
93.89
10 years 32.48
Extreme 32.48
131.54
Manager TitleAgeSince
Chief Executive Officer 53 2024-02-29
Director of Finance/CFO 56 2020-10-30
Investor Relations Contact - 2022-07-31
Director TitleAgeSince
Director/Board Member 69 2015-10-18
Chairman 74 2021-06-08
Director/Board Member 62 2019-06-17
Date Insider Type Main position Quantity % Market Cap.
6/10/26 Other

Director

0 0%
12/15/25 Fiscal year

Executive/Senior Manager

2,350 0.0043%
12/15/25 Fiscal year

Director

4,979 0.0091%
Change 5-day change 1-year change 3-year change Capi.($)
-8.41%-4.03%+83.40%+36.88% 4.69B
+0.24%-2.12%-19.11%-1.80% 182B
-0.24%-1.77%-4.10%+2.32% 110B
+3.57%-0.44%+8.51%+71.16% 59.59B
-2.32%+6.17%+35.49%+51.47% 55.04B
+0.32%+1.34%-3.52%-36.98% 46.87B
-12.79%-8.52% - - 35.55B
-4.92%+10.01%+9.54%-31.31% 32.81B
+0.65%+4.02%+46.96%-6.41% 24.54B
-0.06%-0.90%+3.95%+2.96% 22.69B
Average -2.39%+0.90%+17.90%+9.81% 57.46B
Weighted average by Cap. -0.91%+0.18%+0.56%+8.02%

Financials

2026 *2027 *
Net sales 1.51B 1.31B 1.22B 1.12B 2.12B 144B 2.14B 14.35B 5.63B 71.96B 5.68B 5.56B 238B 1.62B 1.4B 1.31B 1.2B 2.27B 154B 2.29B 15.35B 6.03B 77B 6.08B 5.94B 255B
Net income 159M 138M 128M 118M 223M 15.13B 225M 1.51B 592M 7.57B 597M 584M 25.06B 190M 164M 153M 141M 266M 18.04B 269M 1.8B 706M 9.03B 712M 697M 29.89B
Net Debt - -
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
3,300
Date Price Change Volume
26-08-05 US$78.15 -8.41% 1,862,507
26-08-04 US$85.33 +3.47% 1,284,874
26-08-03 US$82.46 +2.89% 660,617
26-07-31 US$80.14 -1.12% 514,696
26-07-30 US$81.05 -0.47% 645,769
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
78.14USD
Average target price
86.00USD
Spread / Average Target
+10.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LIVN Stock